10.3 Mixed Ventilatory Defects, Isolated Diffusion Defects, and Reversibility Protocols

10.3 Mixed Ventilatory Defects, Isolated Diffusion Defects, and Reversibility Protocols

Complex pulmonary function interpretation requires synthesizing multiple test modalities to identify overlapping physiological abnormalities and evaluate therapeutic responsiveness. When airflow obstruction and lung volume restriction coexist, or when gas exchange is impaired independently of mechanical lung function, specialized diagnostic criteria must be applied.

This section covers the diagnostic definitions of mixed ventilatory defects, the differential diagnosis of isolated diffusion defects, standardized bronchodilator reversibility protocols, and presents a master step-by-step diagnostic decision tree for the NBRC CPFT examination.

---

Mixed Ventilatory Defects

A mixed ventilatory defect represents the concurrent coexistence of both an obstructive ventilatory defect and a restrictive ventilatory defect in the same patient.

Diagnostic Criteria

To definitively establish a mixed ventilatory defect, PFT results must satisfy BOTH of the following physiological thresholds:

1. Airflow Obstruction: The measured $FEV_1/FVC$ ratio is below the Lower Limit of Normal ($FEV_1/FVC < \text{LLN}$ or $< 0.70$).
2. Lung Volume Restriction: Total Lung Capacity is below the Lower Limit of Normal ($TLC < \text{LLN}$ or $< 80%$ predicted).

$\text{Mixed Ventilatory Defect} = (FEV_1/FVC < \text{LLN}) \quad \mathbf{\text{AND}} \quad (TLC < \text{LLN})$

Physiological Mechanisms and Etiologies

• Severe Airflow Obstruction with Secondary Fibrosis / Overlap: Severe COPD or emphysema occurring in a patient who subsequently develops Idiopathic Pulmonary Fibrosis (Combined Pulmonary Fibrosis and Emphysema - CPFE).
• Asthma with Structural Thoracic Disease: Severe persistent asthma in a patient with coexisting kyphoscoliosis or severe morbid obesity.
• Granulomatous Diseases: Advanced Sarcoidosis or pneumoconiosis, which cause both central airway narrowing (obstruction) and extensive parenchymal scarring (restriction).

Diagnostic Caution: In severe airflow obstruction, severe air trapping elevates Residual Volume ($RV$) so dramatically that Forced Vital Capacity ($FVC$) is reduced. This produces a low $FVC$ with a low $FEV_1/FVC$ ratio. If $TLC$ is measured and found to be normal or elevated ($TLC \ge \text{LLN}$), the patient has a pure obstructive defect with air trapping, NOT a mixed defect. Only a confirmed $TLC < \text{LLN}$ validates a true mixed defect.

---

Isolated Diffusion Defects

An isolated diffusion defect occurs when gas transfer across the alveolar-capillary membrane is pathologically impaired despite completely normal mechanical lung properties.

Diagnostic Criteria

1. Spirometry: Normal ($FEV_1/FVC \ge \text{LLN}$ and $FVC \ge \text{LLN}$).
2. Lung Volumes: Normal ($TLC \ge \text{LLN}$ and $RV \ge \text{LLN}$).
3. Diffusing Capacity: Reduced ($DLCO < \text{LLN}$ or $< 80%$ predicted).

$\text{Isolated Diffusion Defect} = (FEV_1/FVC \ge \text{LLN}) + (TLC \ge \text{LLN}) + (DLCO < \text{LLN})$

Differential Diagnosis of Isolated Low $DLCO$

When faced with an isolated low $DLCO$, the technologist must consider four major clinical categories:

1. Pulmonary Vascular Diseases:
   • Pulmonary Arterial Hypertension (PAH): Primary vascular remodeling obliterates pulmonary capillaries without affecting bronchial airways or alveolar spaces.
   • Chronic Thromboembolic Pulmonary Hypertension (CTEPH) / Recurrent PE: Multiple pulmonary emboli obstruct capillary blood flow ($V_c$), dropping $DLCO$.
2. Early Interstitial Lung Disease (ILD):
   • Subclinical fibrotic thickening of the alveolar-capillary membrane ($D_m$) decreases $DLCO$ months or years before structural lung volumes ($TLC$) drop below normal limits.
3. Hematologic Alterations (Anemia):
   • Hemoglobin ($Hb$) is the primary sink for carbon monoxide during the $DLCO$ test. A low blood hemoglobin concentration reduces measured $DLCO$.
   • Mandatory Rule: $DLCO$ values must be mathematically adjusted for patient hemoglobin using standard ATS/ERS correction equations before diagnosing intrinsic vascular or membrane pathology.
4. Opportunistic Infections & Early Infiltrative Disease:
   • Pneumocystis jirovecii pneumonia (PJP) in immunocompromised patients frequently presents with an isolated reduction in $DLCO$ as its earliest diagnostic PFT marker.

\hline \text{Clinical Cause of Low } DLCO & \text{Primary Physiological Mechanism} & DLCO/V_A \text{ Ratio} \\ \hline \text{Pulmonary Arterial Hypertension} & \text{Loss of pulmonary capillary bed volume } (V_c) & \text{Reduced } (< \text{LLN}) \\ \text{Severe Anemia (Uncorrected)} & \text{Reduced hemoglobin binding sites} & \text{Normal when corrected for Hb} \\ \text{Early Scleroderma / ILD} & \text{Alveolar membrane thickening } (D_m) & \text{Reduced } (< \text{LLN}) \\ \text{Emphysema (Obstructive)} & \text{Alveolar wall destruction + capillary loss} & \text{Reduced } (< \text{LLN}) \\ \hline \end{array}$$ --- ## Bronchodilator Reversibility Protocol and ATS/ERS Criteria Evaluating post-bronchodilator responsiveness is an essential component of diagnostic spirometry, helping differentiate reversible airway disease (asthma) from fixed airflow obstruction (COPD). ### Medication Withholding Times Prior to Testing To establish a valid pre-bronchodilator baseline, bronchodilators are withheld per the ATS/ERS 2019 schedule: **SABA 4–6 h**, **SAMA (ipratropium) 12 h**, **LABA (formoterol, salmeterol) 24 h**, **ultra-LABA (indacaterol, vilanterol, olodaterol) 36 h**, and **LAMA (tiotropium, umeclidinium, aclidinium, glycopyrronium) 36–48 h**. If the clinical question is whether function improves *beyond* the current regimen, ATS/ERS permits the patient to continue usual therapy, with that decision documented on the report. ### Administration Protocol 1. Perform baseline pre-bronchodilator spirometry meeting ATS/ERS repeatability criteria. 2. Administer **4 individual puffs of Albuterol** ($90 \text{ mcg/puff}$ USP or $100 \text{ mcg/puff}$ actuarial) via a metered-dose inhaler (MDI) with a valved holding chamber (spacer), waiting 30 seconds between inhalations. 3. Wait **10 to 15 minutes**, then repeat forced spirometry. ### Two Published Criteria for a Positive Response **1. The classic criterion (still in wide clinical and NBRC use):** an increase in $FEV_1$ **or** $FVC$ of **$\ge 12\%$ AND $\ge 200\text{ mL}$** relative to the pre-bronchodilator baseline. Both conditions must be satisfied by the same parameter — a 15% rise that equals only 150 mL is negative. $$\text{Percent Change} = \frac{\text{Post-BD Value} - \text{Pre-BD Value}}{\text{Pre-BD Value}} \times 100$$ **2. The current criterion (ATS/ERS 2022 interpretive strategies):** an increase in $FEV_1$ **or** $FVC$ of **more than 10% of the patient's predicted value**. $$\text{Response (2022)} = \frac{\text{Post-BD Value} - \text{Pre-BD Value}}{\text{Predicted Value}} \times 100 > 10\%$$ The 2022 task force moved to a percent-**predicted** denominator because expressing change as a percentage of a small baseline systematically over-calls reversibility in severe obstruction, where a tiny absolute gain is a large percentage of a tiny baseline, and under-calls it in patients whose baseline is near normal. Teach and recognize both frameworks: items written before 2022 use 12% + 200 mL, and clinical reports increasingly carry the percent-predicted form. > **Worked comparison.** Baseline $FEV_1$ 1.60 L, predicted 3.20 L, post-BD 1.82 L. Absolute change 0.220 L. Classic criterion: 220 mL is $\ge 200$ mL and 13.75% is $\ge 12\%$, so **positive**. 2022 criterion: 0.220 / 3.20 = 6.9% of predicted, which is not $> 10\%$, so **negative**. Identical data, opposite conclusions — which is exactly why the report must state the criterion applied. --- ## Master Step-by-Step PFT Interpretation Decision Tree When analyzing complete PFT panel data on the CPFT exam, follow this standardized 5-step decision algorithm: ``` Step 1: Inspect FEV1/FVC Ratio ├── Below LLN (< 0.70) ──► OBSTRUCTION PRESENT ──► Go to Step 2 └── Normal/High (>= LLN) ─► NO OBSTRUCTION ──────► Go to Step 3 Step 2: Inspect TLC (Airflow Obstruction Branch) ├── TLC < LLN ──────────► MIXED VENTILATORY DEFECT (Obstructive + Restrictive) └── TLC >= LLN ─────────► PURE OBSTRUCTIVE VENTILATORY DEFECT ├── Evaluate FEV1 % Predicted for Severity ├── Check DLCO (Low = Emphysema; Normal = Bronchitis/Asthma) └── Check BD Reversibility (+12% and +200 mL) Step 3: Inspect TLC (Non-Obstructive Branch) ├── TLC < LLN ──────────► PURE RESTRICTIVE VENTILATORY DEFECT │ ├── Check DLCO (Low = Parenchymal Fibrosis) │ └── Check DLCO & RV/TLC (Normal DLCO + High RV/TLC = Neuromuscular/Chest Wall) └── TLC >= LLN ─────────► LUNG VOLUMES NORMAL ───► Go to Step 4 Step 4: Inspect DLCO (Spirometry & Volumes Normal) ├── DLCO < LLN ─────────► ISOLATED DIFFUSION DEFECT (Pulmonary Vascular, Early ILD, Anemia) └── DLCO >= LLN ────────► NORMAL PULMONARY FUNCTION TEST ```